Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma

PURPOSE: In classical Hodgkin lymphoma (HL), the malignant Reed-Sternberg cells express the cell surface marker CD30. Brentuximab vedotin (BV) is an antibody-drug conjugate that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive cells. Although BV elicits...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Cancer Res
Päätekijät: Chen, Robert, Herrera, Alex F., Hou, Jessie, Chen, Lu, Wu, Jun, Guo, Yuming, Synold, Timothy W., Ngo, Vu N., Puverel, Sandrine, Mei, Matthew, Popplewell, Leslie, Yi, Shuhua, Song, Joo Y., Tao, Shu, Wu, Xiwei, Chan, Wing C, Forman, Stephen J., Kwak, Larry W., Rosen, Steven T., Newman, Edward M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056527/
https://ncbi.nlm.nih.gov/pubmed/31811017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1768
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia